Literature DB >> 11571702

Interferon beta-1a in children with multiple sclerosis is well tolerated.

E Waubant1, J Hietpas, T Stewart, Z Dyme, J Herbert, J Lacy, C Miller, M Rensel, S Schwid, D Goodkin.   

Abstract

BACKGROUND: Multiple sclerosis is a chronic demyelinating disease rare in children. Currently marketed disease modifying therapies are limited to adults.
OBJECTIVE: To determine the tolerability of interferon beta-1a (IFNB-1 a) 30 mcg injected intramuscularly once a week in children with clinically definite relapsing-remitting multiple sclerosis (RRMS). DESIGN/
METHODS: A standardized questionnaire was sent to neurologists in the United States to determine the tolerability of IFNB-1 a in patients younger than 16 years.
RESULTS: Tolerability data were available for 9 of 33 children who were reported to initiate IFNB-1 a. Mean age on initiating treatment was 12.7 years (range 8 - 15) and mean duration of therapy was 17 months (range 5 - 36). No patient discontinued therapy due to an adverse event.
CONCLUSIONS: Preliminary data indicate that weekly intramuscular injections of IFNB-1 a are well tolerated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11571702     DOI: 10.1055/s-2001-17370

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  25 in total

1.  Childhood multiple sclerosis and related disorders.

Authors:  Amna Al-Futaisi
Journal:  Oman Med J       Date:  2007-10

Review 2.  First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Authors:  Jessica Johnston; Tsz-Yin So
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

Review 3.  IVIG therapy in neurological disorders of childhood.

Authors:  Juan J Archelos; Franz Fazekas
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 4.  Therapies for multiple sclerosis: considerations in the pediatric patient.

Authors:  Brenda Banwell; Amit Bar-Or; Gavin Giovannoni; Russell C Dale; Marc Tardieu
Journal:  Nat Rev Neurol       Date:  2011-01-11       Impact factor: 42.937

5.  Pediatric multiple sclerosis.

Authors:  Yashma Patel; Vikram Bhise; Lauren Krupp
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

Review 6.  Disease-modifying therapy of pediatric multiple sclerosis.

Authors:  Tanuja Chitnis
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

7.  Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis.

Authors:  Keith Van Haren; Beren H Tomooka; Brian A Kidd; Brenda Banwell; Amit Bar-Or; Tanuja Chitnis; Silvia N Tenembaum; Daniela Pohl; Kevin Rostasy; Russell C Dale; Kevin C O'Connor; David A Hafler; Lawrence Steinman; William H Robinson
Journal:  Mult Scler       Date:  2013-04-23       Impact factor: 6.312

8.  Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

Authors:  Alberto Spalice; Pasquale Parisi; Laura Papetti; Francesco Nicita; Fabiana Ursitti; Francesca Del Balzo; Enrico Properzi; Alberto Verrotti; Martino Ruggieri; Paola Iannetti
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

Review 9.  Pediatric multiple sclerosis.

Authors:  Brenda L Banwell
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

10.  Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.

Authors:  Angelo Ghezzi; Maria Pia Amato; Pietro Annovazzi; Marco Capobianco; Paolo Gallo; Loredana La Mantia; Maria Giovanna Marrosu; Vittorio Martinelli; Nicoletta Milani; Lucia Moiola; Francesco Patti; Carlo Pozzilli; Maria Trojano; Mauro Zaffaroni; Giancarlo Comi
Journal:  Neurol Sci       Date:  2009-04-22       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.